CL2022001985A1 - Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores - Google Patents
Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadoresInfo
- Publication number
- CL2022001985A1 CL2022001985A1 CL2022001985A CL2022001985A CL2022001985A1 CL 2022001985 A1 CL2022001985 A1 CL 2022001985A1 CL 2022001985 A CL2022001985 A CL 2022001985A CL 2022001985 A CL2022001985 A CL 2022001985A CL 2022001985 A1 CL2022001985 A1 CL 2022001985A1
- Authority
- CL
- Chile
- Prior art keywords
- alpha
- fatty acids
- medical uses
- biomarkers
- hydroxylated fatty
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES202030070A ES2846824B2 (es) | 2020-01-29 | 2020-01-29 | Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos |
| EP20382145 | 2020-02-28 | ||
| ES202031155A ES2911474B2 (es) | 2020-11-17 | 2020-11-17 | Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001985A1 true CL2022001985A1 (es) | 2023-02-03 |
Family
ID=77078835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001985A CL2022001985A1 (es) | 2020-01-29 | 2022-07-21 | Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230097753A1 (https=) |
| EP (1) | EP4098649A4 (https=) |
| JP (1) | JP7736313B2 (https=) |
| KR (1) | KR20220132552A (https=) |
| CN (1) | CN115052852A (https=) |
| AU (2) | AU2021212330A1 (https=) |
| BR (1) | BR112022015172A2 (https=) |
| CA (2) | CA3166307C (https=) |
| CL (1) | CL2022001985A1 (https=) |
| IL (1) | IL295120A (https=) |
| MX (1) | MX2022009035A (https=) |
| WO (1) | WO2021152201A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| ES2982396A1 (es) * | 2023-03-14 | 2024-10-15 | Veritas Therapeutics S L | 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1147221B (de) * | 1958-06-28 | 1963-04-18 | Dr Rer Nat Gernot Grimmer | Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der Pentadecen- und Heptadecensaeuren |
| DE1195296B (de) * | 1958-06-28 | 1965-06-24 | Dr Gernot Grimmer | Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure |
| GB1156465A (en) * | 1967-02-16 | 1969-06-25 | Unilever Ltd | Prostaglandins |
| US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB9926833D0 (en) * | 1999-11-15 | 2000-01-12 | Univ Sunderland | Compositions |
| DE102007055344A1 (de) * | 2007-11-19 | 2009-05-20 | K. D. Pharma Bexbach Gmbh | Neue Verwendung von Omega-3-Fettsäure(n) |
| ES2342997B1 (es) * | 2008-12-09 | 2011-06-06 | Universitat De Les Illes Balears | Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento. |
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| KR20120065276A (ko) | 2009-05-29 | 2012-06-20 | 뉴 챕터, 인코포레이티드. | 지질 조성을 조정하기 위한 조성물 및 방법 |
| CN102276444B (zh) * | 2011-05-04 | 2013-10-09 | 厦门大学 | 脂肪酸类化合物及其制备方法与应用 |
| ES2401629B1 (es) | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
| WO2014113584A1 (en) * | 2013-01-16 | 2014-07-24 | Rhode Island Hospital | Compositions and methods for the prevention and treatment of osteolysis and osteoporosis |
| US20150173410A1 (en) * | 2013-12-19 | 2015-06-25 | Change Cola, Inc. | Beverage comprising omega fatty acid |
| JP2016222590A (ja) * | 2015-05-29 | 2016-12-28 | 国立大学法人東京海洋大学 | 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬 |
| WO2019241728A1 (en) * | 2018-06-15 | 2019-12-19 | Youhealth Biotech, Limited | Composition and methods for modulation of elovl2 |
-
2021
- 2021-01-28 CN CN202180011594.4A patent/CN115052852A/zh active Pending
- 2021-01-28 AU AU2021212330A patent/AU2021212330A1/en not_active Abandoned
- 2021-01-28 WO PCT/ES2021/070068 patent/WO2021152201A2/es not_active Ceased
- 2021-01-28 CA CA3166307A patent/CA3166307C/en active Active
- 2021-01-28 JP JP2022542038A patent/JP7736313B2/ja active Active
- 2021-01-28 BR BR112022015172A patent/BR112022015172A2/pt unknown
- 2021-01-28 MX MX2022009035A patent/MX2022009035A/es unknown
- 2021-01-28 EP EP21748005.2A patent/EP4098649A4/en active Pending
- 2021-01-28 IL IL295120A patent/IL295120A/en unknown
- 2021-01-28 US US17/759,782 patent/US20230097753A1/en active Pending
- 2021-01-28 KR KR1020227027634A patent/KR20220132552A/ko active Pending
- 2021-01-28 CA CA3233141A patent/CA3233141A1/en active Pending
-
2022
- 2022-07-21 CL CL2022001985A patent/CL2022001985A1/es unknown
-
2023
- 2023-10-13 AU AU2023248158A patent/AU2023248158B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL295120A (en) | 2022-09-01 |
| CA3233141A1 (en) | 2021-08-05 |
| JP7736313B2 (ja) | 2025-09-09 |
| CN115052852A (zh) | 2022-09-13 |
| EP4098649A2 (en) | 2022-12-07 |
| US20230097753A1 (en) | 2023-03-30 |
| EP4098649A4 (en) | 2024-04-17 |
| MX2022009035A (es) | 2022-08-11 |
| AU2023248158B2 (en) | 2025-11-27 |
| WO2021152201A2 (es) | 2021-08-05 |
| AU2021212330A1 (en) | 2022-09-22 |
| CA3166307A1 (en) | 2021-08-05 |
| BR112022015172A2 (pt) | 2022-10-11 |
| WO2021152201A3 (es) | 2021-09-23 |
| AU2023248158A1 (en) | 2023-11-02 |
| KR20220132552A (ko) | 2022-09-30 |
| CA3166307C (en) | 2024-05-21 |
| JP2023518640A (ja) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| MX2020007479A (es) | Profármacos de ketamina, composiciones y usos de los mismos. | |
| MX370903B (es) | Composiciones de ácido percarboxílico estables y sus usos. | |
| CL2022001985A1 (es) | Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores | |
| ECSP22051247A (es) | Fluoroalquil-oxadiazoles y sus usos | |
| MX2021009652A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| CL2021000750A1 (es) | Combinación beneficiosa de agentes de control biológico bacterianos y ácidos grasos | |
| CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| DOP2012000314A (es) | Compuestos, composiciones de tiocetato y metodos de uso | |
| CR20110353A (es) | Compuestos de tiazolopiridina moduladores de sirtuina referencia cruzada | |
| MX2025014414A (es) | Composiciones de éster de ácido cannabinoide y sus usos | |
| CR11648A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas | |
| DOP2014000159A (es) | Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre | |
| CO6351742A2 (es) | Compuestos organicos para la cicatrizacion de heridas | |
| CO2018001628A2 (es) | Composiciones y formulaciones antimicrobianas | |
| MX2017014245A (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas. | |
| CO2019013013A2 (es) | Inhibidores pirazólicos de magl | |
| NO20071485L (no) | Kjemiske substanser. | |
| CL2011002160A1 (es) | Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. | |
| BR112019012100A2 (pt) | composições para higiene bucal e métodos para aumentar a estabilidade das mesmas | |
| UY39368A (es) | Composiciones para modular el empalme | |
| CR20110226A (es) | Composición para tratar enfermedad | |
| CL2021001830A1 (es) | Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa | |
| MX2025008528A (es) | Sal de s-oxprenolol | |
| MX2013015419A (es) | Dha y epa en la reduccion de estres oxidante. |